Applications of dendrimers for brain delivery and cancer therapy

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2403-2414

  Somani, Sukrut ^a   Dufès, Christine ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

brain delivery; cancer therapy; dendrimer; gene therapy; tumor targeting

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DENDRIMER; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUCOSE TRANSPORTER 1; GONADORELIN; IMINE; LACTOFERRIN; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; METHOTREXATE; NANOCARRIER; PACLITAXEL; POLYAMIDOAMINE; POLYPROPYLENIMINE; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; GENE TARGETING; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAGNETIC FIELD; MAGNETOSOME; MEMBRANE TRANSPORT; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; REVIEW; BRAIN; BRAIN NEOPLASMS; METABOLISM;

BRAIN; BRAIN NEOPLASMS; DENDRIMERS; HUMANS;

EID: 84912061776     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.130     Document Type: Review

References (76)

1. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005).
2. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12(1-2), 54-61 (2007).
3. WHO. Cancer, Fact sheet no 297 (2014). www.who.int/mediacentre/factsheets/fs297/en/ 4 Tomalia DA, Baker H, Dewald J et al. A new class of polymers: starburst-dendritic macromolecules. Polym. J. 17, 117-132 (1985).
4. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 15(5-6), 171-185 (2010).
5. Buhleier E, Wehner W, Vögtle F. 'Cascade' and 'nonskid-chain-like' syntheses of molecular cavity topologies. Synthesis 2, 155-158 (1978).
6. Tomalia DA, Baker H, Dewald J et al. Dendritic macromolecules -synthesis of starburst dendrimers. Macromolecules 19, 2466-2468 (1986).
7. Newkome GR, Yao ZQ, Baker GR, Gupta VK. Micelles. Part 1. Cascade molecules -a new approach to micelles -a [27]-arborol. J. Org. Chem. 50, 2003-2004 (1985).
8. Newkome GR, Yao ZQ, Baker GR, Gupta VK, Russo PS, Saunders MJ. Cascade molecules. Part 2. Synthesis and characterization of a benzene [9]3-arborol. J. Am. Chem. Soc. 108, 849-850 (1986).
9. Esfand R, Tomalia DA. Poly (amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6(8), 427-436 (2001).
10. Hawker CJ, Fréchet JMJ. Preparation of polymers with controlled molecular architecture -a new convergent approach to dendritic macromolecules. J. Am. Chem. Soc. 112, 7638-7647 (1990).
11. Liu M, Fréchet JMJ. Designing dendrimers for drug delivery. Pharm. Sci. Technol. Today 2(10), 393-401 (1999).
12. Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev. 40(1), 173-190 (2011).
13. Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem. Neurosci. 5(1), 2-13 (2014).
14. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliv. Rev. 60(9), 1037-1055 (2008).
15. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 2, 106-113 (1996).
16. Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell. Mol. Neurobiol. 20, 149-163 (2000).
17. Abbott, NJ. Physiology of the blood-brain barrier and its consequences for drug transport to the brain. Int. Congr. Ser. 1277, 3-18 (2005).
18. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223-236 (2006).
19. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53 (2006).
20. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 312, 162-163 (1984).
21. Dufès C, Al Robaian M, Somani S. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells, Ther. Deliv. 4, 629-640 (2013).
22. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 21, 1117-1125 (2007).
23. Fisher D, Kissel T. Histochemical characterization of primary capillary endothelial cells from porcine brains using monoclonal antibodies and fluorescein isothiocyanate-labelled lectins: implications for drug delivery. Eur. J. Pharm. Biopharm. 52, 1-11 (2001).
24. Mo Y, Lim, L. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation. J. Control. Release 108, 244-262 (2005).
25. He H, Li Y, Jia XR et al. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32(2), 478-487 (2011).
26. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z. Lack of interactions between breast cancer resistance protein (BCRP/ABCG2) and selected antiepileptic agents. Epilepsia 47(3), 461-468 (2006).
27. Tian W, Ying X, Du J et al. Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur. J. Pharm. Sci. 41(2), 232-243 (2010).
28. Ferretti C, Blengio M, Ghi P, Racca S, Genazzani E, Portaleone P. Tamoxifen counteracts estradiol induced effects on striatal and hypophyseal dopamine receptors. Life Sci. 42(24), 2457-2465 (1988).
29. Kayyali R, Marriott C, Wiseman H. Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett. 344(2-3), 221-224 (1994).
30. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33(15), 3899-3908 (2012).
31. Kabanov VA, Zezin AB, Rogacheva VB et al. Polyelectrolyte behavior of astramol poly(propyleneimine) dendrimers. Macromolecules 31(15), 5142-5144 (1998).
32. Somani S, Blatchford DR, Millington O, Stevenson ML, Dufès C. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J. Control. Release 188, 78-86 (2014).
33. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108(6), 779-784 (2001).
34. Fillebeen C, Descamps L, Dehouck MP et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274(11), 7011-7017 (1999).
35. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29(2), 238-246 (2008).
36. Huang R, Ke W, Han L et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J. Cereb. Blood Flow Metab. 29(12), 1914-1923 (2009).
37. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4), 1534-1544 (2008).
38. Ke W, Shao K, Huang R et al. Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30(36), 6976-6985 (2009).
39. Huang R, Ma H, Guo Y et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson's disease. Pharm. Res. 30(10), 2549-2559 (2013).
40. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. studies with quantitative western blotting and in situ hybridization. J. Biol. Chem. 265(29), 18035-18040 (1990).
41. Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm. 5(1), 105-116 (2008).
42. Golden PL, MacCagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99(1), 14-18 (1997).
43. Barrett GL, Trieu J, Naim T. The identification of leptin-derived peptides that are taken up by the brain. Regul. Pept. 155(1-3), 55-61 (2009).
44. Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31(19), 5246-5257 (2010).
45. Han L, Zhang A, Wang H, Pu P, Kang C, Chang J. Construction of novel brain-targeting gene delivery system by natural magnetic nanoparticles. J Appl. Polym. Sci. 121, 3446-3454 (2011).
46. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP. Transferrin receptor 2-alpha supports cell growth in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275(22), 16618-16625 (2000).
47. Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch. A Pathol Anat. Histopathol. 416(6), 491-496 (1990).
48. Maeda H, Matsumura Y. A new concept in macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12 Pt 1), 6387-9392 (1986).
49. Morgan MT, Carnahan MA, Finkelstein S et al. Dendritic supramolecular assemblies for drug delivery. Chem. Commun. 34(14), 4309-4311 (2005).
50. Morgan MT, Nakanishi Y, Kroll DJ et al. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 66(24), 11913-11921 (2006).
51. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10(8), 767-776 (1999).
52. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11(6), 910-917 (2000).
53. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int. J. Pharm. 302(1-2), 29-38 (2005).
54. Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug. Chem. 16(2), 397-405 (2005).
55. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257(1-2), 111-124 (2003).
56. Neerman MF, Chen HT, Parrish AR, Simanek EE. Reduction of drug toxicity using dendrimers based on melamine. Mol. Pharm. 1(5), 390-393 (2004).
57. Wu G, Barth RF, Yang WL, Kawabata S, Zhang LW, Green- Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1), 52-59 (2006).
58. Ooya T, Lee J, Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug. Chem. 15(6), 1221-1229 (2004).
59. Duncan R, Malik N. Dendrimers: biocompatibility and potential for delivery of anticancer agents. Proc. Int. Symp. Control. Release Bioact. Mater. 23, 105-106 (1996).
60. Lee CC, Gillies ER, Fox ME et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA 103(45), 16649-16654 (2006).
61. Thomas TP, Majoros IJ, Kotlyar A et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J. Med. Chem. 48(11), 3729-3735 (2005).
62. Maruyama-Tabata H, Harada Y, Matsumura T et al. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene Ther. 7(1), 53-60 (2000).
63. Sato N, Kobayashi H, Saga T et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo- DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 7(11), 3606-3612 (2001).
64. Bai CZ, Choi S, Nam K, An S, Park JS. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int. J. Pharm. 445(1-2), 79-87 (2013).
65. Shen XC, Zhou J, Liu X et al. Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/ dendrimer complexes. Org. Biomol. Chem. 5, 3674-3681 (2007).
66. Liu X, Liu C, Laurini E et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol. Pharm. 9(3), 470-481 (2012).
67. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 32(4), 1242-1252 (2011).
68. Huang S, Li J, Han L et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 32(28), 6832-6838 (2011).
69. Han L, Zhang A, Wang H et al. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum. Gene Ther. 21(4), 417-426 (2010).
70. Taratula O, Garbuzenko OB, Kirkpatrick P et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 140(3), 284-293 (2009).
71. Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 8(1), 59-69 (2011).
72. Dufès C, Keith WN, Bisland A, Proutski I, Uchegbu IF, Schätzlein AG. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumours. Cancer Res. 65(18), 8079-8084 (2005).
73. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57(15), 2177-2202 (2005).
74. Koppu S, Oh YJ, Edrada-Ebel R et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control. Release 143(2), 215-221 (2010).
75. Al Robaian M, Chiam KY, Blatchford DR, Dufès C. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. Nanomedicine 9(4), 421-434 (2014).
76. Lemarié F, Croft DR, Tate RJ, Ryan KM, Dufès C. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. Biomaterials 33(9), 2701-2709 (2012).